Marija Gjorgjievska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marija Gjorgjievska has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Dijana Plaseska-Karanfilska
Research Centre for Genetic Engineering and Biotechnology "Georgi D. Efremov", Macedonian Academy of Science and Arts, Skopje, North Macedonia
2 shared publications - Gjorgji Bozhinovski
Research Centre for Genetic Engineering and Biotechnology "Georgi D. Efremov", Macedonian Academy of Science and Arts, Skopje, North Macedonia
2 shared publications - Aimilios Lallas
Aristotle University of Thessaloniki Thessaloniki Greece
1 shared publication Andzelka Ilieva
Zan Mitrev Clinic Skopje Republic of Macedonia
1 shared publication- Djansel Bukovec
Zan Mitrev Clinic Skopje Republic of Macedonia
1 shared publication - Elena Sukarova-Angelovska
Department of Endocrinology and Genetics, University Clinic for Pediatric Diseases, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Skopje, Republic of North Macedonia
1 shared publication
Latest Publications
- 24 October 2026
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 39 (6)
Mutations in Chromatin Regulator Genes Associate With TMB and Immunotherapy Response in Melanoma
Melanoma is a high‐tumor‐mutational‐burden (TMB) cancer, largely driven by ultraviolet‐induced DNA damage. Although TMB predicts response to immune checkpoint inhibitors (ICIs), the genomic factors underlying its variability remain unclear. In addition to canonical DNA‐repair defects such as mismatch repair (MMR) and POLE/POLD1 mutations, alterations in chromatin regulators (CRs) may influence genome stability and mutational load. We analyzed melanoma cohorts from the MSK‐ICI, TCGA, MSK‐Met, DFCI, and UCLA datasets. TMB was compared between CR‐mutant and CR–wild‐type tumors and overall cohorts, along with gene‐level analyses of individual CRs. Associations between the number of CR mutations and TMB were assessed. Overall survival (OS) in ICI‐treated patients was evaluated using Kaplan–Meier and Cox models, with TCGA as a non–ICI‐treated comparator. Across datasets, CR‐mutant melanomas consistently exhibited significantly higher TMB than CR–wild‐type tumors. Several CRs were linked to elevated TMB, comparable to MMR‐ or POLE/POLD1‐mutant tumors. Multiple CR alterations showed a positive linear relationship with TMB. In ICI‐treated cohorts, CR‐mutant tumors had significantly longer OS, while this link was not observed in non–ICI‐treated cases. These findings suggest that CR mutations define a subset of melanomas with high TMB and improved response to ICIs, warranting prospective validation as predictive biomarkers.
- 24 October 2026
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 39 (6)
Mutations in Chromatin Regulator Genes Associate With TMB and Immunotherapy Response in Melanoma
Melanoma is a high‐tumor‐mutational‐burden (TMB) cancer, largely driven by ultraviolet‐induced DNA damage. Although TMB predicts response to immune checkpoint inhibitors (ICIs), the genomic factors underlying its variability remain unclear. In addition to canonical DNA‐repair defects such as mismatch repair (MMR) and POLE/POLD1 mutations, alterations in chromatin regulators (CRs) may influence genome stability and mutational load. We analyzed melanoma cohorts from the MSK‐ICI, TCGA, MSK‐Met, DFCI, and UCLA datasets. TMB was compared between CR‐mutant and CR–wild‐type tumors and overall cohorts, along with gene‐level analyses of individual CRs. Associations between the number of CR mutations and TMB were assessed. Overall survival (OS) in ICI‐treated patients was evaluated using Kaplan–Meier and Cox models, with TCGA as a non–ICI‐treated comparator. Across datasets, CR‐mutant melanomas consistently exhibited significantly higher TMB than CR–wild‐type tumors. Several CRs were linked to elevated TMB, comparable to MMR‐ or POLE/POLD1‐mutant tumors. Multiple CR alterations showed a positive linear relationship with TMB. In ICI‐treated cohorts, CR‐mutant tumors had significantly longer OS, while this link was not observed in non–ICI‐treated cases. These findings suggest that CR mutations define a subset of melanomas with high TMB and improved response to ICIs, warranting prospective validation as predictive biomarkers.
- Open Access
- 9 July 2026
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 43 (7) , 407-410
Genotype-Phenotype Correlation in Tuberous Sclerosis Complex: Insights from North Macedonia
- 9 July 2026
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 43 (7) , 407-410
Open AccessGenotype-Phenotype Correlation in Tuberous Sclerosis Complex: Insights from North Macedonia
- Open Access
- 12 July 2023
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 40 (4) , 252-261
Mutational Spectrum and Genotype-phenotype Correlations in Neurofibromatosis Type 1 Patients from North Macedonia: Identification of Ten Novel NF1 Pathogenic Variants
Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disorder, characterized by multiple café-au-lait macules, axillary and inguinal freckling, tumors of the nervous system, and iris hamartomas. More than 3,100 different pathogenic variants have been reported in the NF1 gene, including missense, nonsense, frameshift, in-frame, splicing, and large deletions. To determine the NF1 mutational spectrum in patients with NF1 from the Republic of North Macedonia. A cohort study. Molecular analyses included reverse transcription and cDNA sequencing of the NF1 gene and next-generation sequencing using the TruSight Cancer panel, along with the multiple ligation probe amplification method to detect single nucleotide variants and copy number variations. Direct DNA sequencing was also used for the family member analysis. Our 9-year study of patients suspected of having NF1 in the Republic of North Macedonia encompassed molecular characterization of 30 cases of the disease. We identified 28 unique pathogenic NF1 variants (NM_001042492.3), of which ten were novel: c.208delA; c.341_364del; c.1480_1481delTT; c.2325+1G>C; c.2495_2496dupAC; c.2533_2541del; c.4517delC; c.5844C>G; c.6971delA; c.7605_7606delGAinsAT. In addition to the variant spectrum analysis, our research revealed two positive genotype-phenotype correlations. One between the clinical manifestation of cognitive impairment and gross deletions in the NF1 gene, and the other between cognitive impairment and truncating variants located in the RAS-GAP functional domain. This is the first study of NF1 patients in the Republic of North Macedonia, and it contributes ten novel variants to the global spectrum of pathogenic NF1 variants. It also corroborates the crucial importance of NF1 genetic testing for a prompt and precise diagnosis, particularly in younger patients.
- 12 July 2023
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 40 (4) , 252-261
Open AccessMutational Spectrum and Genotype-phenotype Correlations in Neurofibromatosis Type 1 Patients from North Macedonia: Identification of Ten Novel NF1 Pathogenic Variants
Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disorder, characterized by multiple café-au-lait macules, axillary and inguinal freckling, tumors of the nervous system, and iris hamartomas. More than 3,100 different pathogenic variants have been reported in the NF1 gene, including missense, nonsense, frameshift, in-frame, splicing, and large deletions. To determine the NF1 mutational spectrum in patients with NF1 from the Republic of North Macedonia. A cohort study. Molecular analyses included reverse transcription and cDNA sequencing of the NF1 gene and next-generation sequencing using the TruSight Cancer panel, along with the multiple ligation probe amplification method to detect single nucleotide variants and copy number variations. Direct DNA sequencing was also used for the family member analysis. Our 9-year study of patients suspected of having NF1 in the Republic of North Macedonia encompassed molecular characterization of 30 cases of the disease. We identified 28 unique pathogenic NF1 variants (NM_001042492.3), of which ten were novel: c.208delA; c.341_364del; c.1480_1481delTT; c.2325+1G>C; c.2495_2496dupAC; c.2533_2541del; c.4517delC; c.5844C>G; c.6971delA; c.7605_7606delGAinsAT. In addition to the variant spectrum analysis, our research revealed two positive genotype-phenotype correlations. One between the clinical manifestation of cognitive impairment and gross deletions in the NF1 gene, and the other between cognitive impairment and truncating variants located in the RAS-GAP functional domain. This is the first study of NF1 patients in the Republic of North Macedonia, and it contributes ten novel variants to the global spectrum of pathogenic NF1 variants. It also corroborates the crucial importance of NF1 genetic testing for a prompt and precise diagnosis, particularly in younger patients.